TransCode Therapeutics, Inc. Releases 2025 Annual Report: Major Developments, Risks, and Opportunities

TransCode Therapeutics, Inc. (Nasdaq: RNAZ) has released its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The report contains critical information for shareholders, including transformative corporate actions, financial health, strategic risks, and forward-looking statements that could materially impact share value.

Key Points and Potentially Price-Sensitive Developments

• Acquisition of Polynoma via ABCJ, LLC
  TransCode has entered into an agreement to acquire ABCJ, LLC, the parent company of Polynoma, LLC. This acquisition is structured through the issuance of Series A and Series B Non-Voting Convertible Preferred Stock. These preferred shares cannot be converted into common stock until shareholder approval is obtained, in line with Nasdaq regulations. The company also agreed to up to \$95 million in contingent milestone payments to the sellers upon the achievement of certain milestones.
  Shareholder Impact: The acquisition and subsequent conversion of preferred stock could cause significant dilution, impact control, and affect the share price both on approval and as milestones are met.
• New Strategic Licensing Agreement with Unleash Immuno Oncolytics, Inc.
  In March 2026, TransCode issued Series C Non-Voting Convertible Preferred Stock to Unleash Immuno Oncolytics for a licensing agreement. Like the Series A and B, these shares are not convertible without shareholder approval.
  Shareholder Impact: This provides TransCode with potential pipeline growth, but risks further dilution and is contingent on a successful shareholder vote.
• Standby Equity Purchase Agreement (SEPA) with Yorkville
  The company entered into a SEPA with YA II PN, LTD (Yorkville), which could result in the potential issuance of additional common shares at TransCode’s discretion. This provides financing flexibility but may be dilutive.
• Multiple Reverse Stock Splits
  The company implemented several reverse stock splits in 2023, 2024, and May 2025 (the most recent being a 1-for-28 split) to comply with Nasdaq listing requirements and manage its share structure. All per-share data have been retroactively adjusted.
• Nasdaq Listing Risks
  TransCode explicitly warns of potential delisting from the Nasdaq Capital Market if it fails to continue meeting listing requirements. Delisting would severely impact liquidity, investor confidence, and share price.
• Going Concern Warning
  The company acknowledges that its ability to continue as a going concern is uncertain. It is dependent on raising additional capital to fund its operations, including R&D, clinical trials, and commercialization efforts. Failure to secure financing could result in severe consequences for shareholders, including insolvency.
• Material Weaknesses in Internal Controls
  TransCode has identified material weaknesses in internal controls over financial reporting. If not remediated, or if new weaknesses emerge, the company may not be able to accurately or timely report financial results, potentially impacting share value and regulatory compliance.
• Highly Dependent on Lead Candidate TTX-MC138
  The company’s future is largely dependent on the success of its lead therapeutic candidate, TTX-MC138, which entered phase I clinical assessment in August 2023. The candidate is still in early development and requires significant funding and regulatory milestones before commercialization.
• Heavy Reliance on Licensed IP and Third Parties
  The business model relies on licensed intellectual property and partnerships. Any disruption or inability to secure/maintain these licenses could undermine the company’s prospects.
• Executive and Board Approvals Required for Major Changes
  The acquisition and licensing deals are subject to shareholder approval. The company has committed to holding a shareholder meeting to vote on these conversions and control changes, meaning investor votes are critical to the company’s future structure and direction.
• Significant Pipeline Milestone Payments
  The company may pay up to \$95 million in milestone payments related to the Polynoma acquisition, which could impact future cash flows and financial flexibility.
• Risk Factors and Forward-Looking Statements
  The report provides a comprehensive list of risks, including financial instability, regulatory hurdles, dependency on single products, volatility of share price, ability to retain key personnel, and vulnerability to economic and geopolitical disruptions.

Other Notable Details for Shareholders

• Common Stock Information: As of April 3, 2026, the number of shares of common stock outstanding is provided (exact number not specified in the extract).
• Nasdaq Symbol: RNAZ.
• Corporate Headquarters: 6 Liberty Square, #2382, Boston, MA 02109.
• SEC Reporting Compliance: The company is current with its SEC filings and is an emerging growth company and a smaller reporting company.

Conclusion

TransCode Therapeutics is at a critical juncture, with transformative acquisitions and licensing agreements pending shareholder approval. The company faces significant risks related to dilution, funding, regulatory approval, Nasdaq listing compliance, internal controls, and the success of its lead product candidate. Shareholders should pay close attention to upcoming votes and SEC filings, as these will materially affect the company’s structure, strategy, and share value.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. Investors should conduct their own due diligence and consult with financial professionals before making investment decisions. The content is based on the company’s public filings, which may be subject to change or revision.

View Transcode Therapeutics, Inc. Historical chart here